Related references
Note: Only part of the references are listed.S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
Shuichi Hironaka et al.
LANCET ONCOLOGY (2016)
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer
Y. Yamada et al.
ANNALS OF ONCOLOGY (2015)
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2015)
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
Young Saing Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
T. Waddell et al.
EJSO (2014)
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
Florian Lordick et al.
GASTRIC CANCER (2014)
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
Wasaburo Koizumi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
Yiming Lu et al.
JOURNAL OF CHEMOTHERAPY (2014)
Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).
In Gyu Hwang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) Study
Rosine Guimbaud et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer
X. Wang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2013)
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer
Dingzhi Huang et al.
EUROPEAN JOURNAL OF CANCER (2013)
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
Koji Oba et al.
EUROPEAN JOURNAL OF CANCER (2013)
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
Salah-Eddin Al-Batran et al.
EUROPEAN JOURNAL OF CANCER (2013)
Gastric Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Tom Waddell et al.
LANCET ONCOLOGY (2013)
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Florian Lordick et al.
LANCET ONCOLOGY (2013)
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
Wei-Chih Liao et al.
LANCET ONCOLOGY (2013)
Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
PLOS ONE (2013)
Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer
Janja Ocvirk et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
A. Roy et al.
BRITISH JOURNAL OF CANCER (2012)
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
E. Mochiki et al.
BRITISH JOURNAL OF CANCER (2012)
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer
Gun Min Kim et al.
EUROPEAN JOURNAL OF CANCER (2012)
A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer
Kazuhiro Nishikawa et al.
GASTRIC CANCER (2012)
What is a multiple treatments meta-analysis?
A. Cipriani et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2012)
Accounting for correlation in network meta-analysis with multi-arm trials
A. J. Franchini et al.
RESEARCH SYNTHESIS METHODS (2012)
Automating network meta-analysis
Gert van Valkenhoef et al.
RESEARCH SYNTHESIS METHODS (2012)
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
Yoshito Komatsu et al.
ANTI-CANCER DRUGS (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A Randomized Phase 2 Study of Docetaxel and S-1 Versus Docetaxel and Cisplatin in Advanced Gastric Cancer With an Evaluation of SPARC Expression for Personalized Therapy
Hei-Cheul Jeung et al.
CANCER (2011)
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis
Francesco Montagnani et al.
GASTRIC CANCER (2011)
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
Hiroyuki Narahara et al.
GASTRIC CANCER (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer
Xiao-Dong Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
M. Moehler et al.
ANNALS OF ONCOLOGY (2010)
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
Jina Yun et al.
EUROPEAN JOURNAL OF CANCER (2010)
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
Jaffer A. Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Chemotherapy for advanced gastric cancer
Anna Dorothea Wagner et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
5-FU/I-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)
A. Sawaki et al.
EJC SUPPLEMENTS (2009)
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
Narikazu Boku et al.
LANCET ONCOLOGY (2009)
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
M. Dank et al.
ANNALS OF ONCOLOGY (2008)
A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
J-L Lee et al.
BRITISH JOURNAL OF CANCER (2008)
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
Vassilis Golfinopoulos et al.
LANCET ONCOLOGY (2007)
Docetaxel, cisplatin, and fluorouracil;: Docetaxel and cisplatin;: and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma:: A randomized phase II trial of the Swiss Group for Clinical Cancer Research
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: Randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
Manfred P. Lutz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil
Se Hoon Park et al.
ANTI-CANCER DRUGS (2006)
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
JA Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma:: A randomized phase II study
PC Thuss-Patience et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:: results of a randomized phase II study
C Pozzo et al.
ANNALS OF ONCOLOGY (2004)
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803
O Bouche et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Combination of direct and indirect evidence in mixed treatment comparisons
G Lu et al.
STATISTICS IN MEDICINE (2004)
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma
G Cocconi et al.
ANNALS OF ONCOLOGY (2003)
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
A Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group
U Vanhoefer et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
